Nuno Mendonça
Directeur Technique/Scientifique/R&D chez AC IMMUNE SA
Fortune : 38 246 $ au 31/05/2024
Profil
Dr. Nuno Mendonça, MD, is a Chief Medical Officer at AC Immune SA. Dr. Mendonça was previously employed as a Senior Medical Director by Novartis Gene Therapies, Inc. He received his doctorate degree from the University of Coimbra.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AC IMMUNE SA
0,01% | 01/03/2024 | 8 225 ( 0,01% ) | 38 246 $ | 31/05/2024 |
Postes actifs de Nuno Mendonça
| Sociétés | Poste | Début |
|---|---|---|
| AC IMMUNE SA | Directeur Technique/Scientifique/R&D | 01/10/2023 |
Anciens postes connus de Nuno Mendonça
| Sociétés | Poste | Fin |
|---|---|---|
| AVEXIS INC | Directeur Technique/Scientifique/R&D | - |
Formation de Nuno Mendonça
| University of Coimbra | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Entreprise privées | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
